1616280-18-2

Upstream product

• 1616280-10-4 5-{5-amino-2-[4-(ethylsulfonyl)phenoxy]phenyl}-1-methylpyrrolidin-2-one 
• 1616280-07-9 5-{5-amino-2-[4-(ethylsulfonyl)phenoxy]-4-iodophenyl}-1-methylpyrrolidin-2-one 
• 541-41-3 chloroformic acid ethyl ester 
• 1616280-05-7 5-{2-[4-(ethylsulfonyl)phenoxy]-5-nitrophenyl}-1-methylpyrrolidin-2-one 
• 7205-79-0 1-(ethylsulfonyl)-4-methoxybenzene 
• 7205-58-5 ethyl (4-methoxyphenyl) sulfide 
• 696-63-9 4-Methoxybenzenethiol 
• 1616279-51-6 5-(2-chloro-5-nitrophenyl)dihydrofuran-2(3H)-one 
• 859537-79-4 4-hydroxy-phenyl-ethylsulfone 
• 6361-21-3 2-chloro-5-nitrobenzaldehyde 
• 1616279-49-2 ethyl 4-(2-chloro-5-nitrophenyl)-4-[(trimethylsilyl)oxy]butanoate 
• 1616279-56-1 5-(2-chloro-5-nitrophenyl)-1-methylpyrrolidin-2-one 
• 1314725-24-0 5-(2-chloro-5-nitrophenyl)pyrrolidin-2-one 
• 1616281-06-1 methyl 4-(2-chloro-5-nitrophenyl)-4-hydroxybutanoate 

Downstream Products

• 1616280-24-0 C₃₀H₃₁N₃O₆S 
• 1616280-27-3 C₂₉H₂₉N₃O₆S 

Relevant academic research and scientific papers

NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT

Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included.